{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:28:11Z","timestamp":1793377691250,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00259-024-06667-0","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T06:07:44Z","timestamp":1710223664000},"page":"2308-2319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["[18F]FDG PET\/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy"],"prefix":"10.1007","volume":"51","author":[{"given":"Jinbo","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7263-7399","authenticated-orcid":false,"given":"Xiaoli","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"1","key":"6667_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"issue":"9","key":"6667_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/nejmra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842\u201358. https:\/\/doi.org\/10.1056\/nejmra2027612","journal-title":"N Engl J Med"},{"issue":"6","key":"6667_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/jco.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u2013U31. https:\/\/doi.org\/10.1200\/jco.2014.56.2025","journal-title":"J Clin Oncol"},{"key":"6667_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-3-030-41008-7_10","volume":"1244","author":"R Nair","year":"2020","unstructured":"Nair R, Westin J. CAR T-cells. Adv Exp Med Biol. 2020;1244:215\u201333. https:\/\/doi.org\/10.1007\/978-3-030-41008-7_10","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"6667_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/cpt.1674","volume":"107","author":"SA Holstein","year":"2020","unstructured":"Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107(1):112\u201322. https:\/\/doi.org\/10.1002\/cpt.1674","journal-title":"Clin Pharmacol Ther"},{"key":"6667_CR6","doi-asserted-by":"publisher","unstructured":"Linguanti F, Abenavoli EM, Berti V, et al. Metabolic imaging in B-cell lymphomas during CAR-T cell therapy. Cancers. 2022;14(19). https:\/\/doi.org\/10.3390\/cancers14194700","DOI":"10.3390\/cancers14194700"},{"issue":"27","key":"6667_CR7","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"21","key":"6667_CR8","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489\u201396. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"key":"6667_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Litiere S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"key":"6667_CR10","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S\u201350S. https:\/\/doi.org\/10.2967\/jnumed.108.057307","journal-title":"J Nucl Med"},{"key":"6667_CR11","doi-asserted-by":"publisher","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32(27):3048\u201358. https:\/\/doi.org\/10.1200\/jco.2013.53.5229","DOI":"10.1200\/jco.2013.53.5229"},{"key":"6667_CR12","doi-asserted-by":"publisher","unstructured":"Hyun OJ, Lodge MA, Wahl RL, Practical PERCIST. A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043","DOI":"10.1148\/radiol.2016142043"},{"issue":"1","key":"6667_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-022-01256-w","volume":"15","author":"WG Breen","year":"2022","unstructured":"Breen WG, Hathcock MA, Young JR, et al. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET\/CT. J Hematol Oncol. 2022;15(1):36. https:\/\/doi.org\/10.1186\/s13045-022-01256-w","journal-title":"J Hematol Oncol"},{"issue":"8","key":"6667_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/rlu.0000000000003756","volume":"46","author":"P Sesques","year":"2021","unstructured":"Sesques P, Tordo J, Ferrant E, et al. Prognostic impact of 18F-FDG PET\/CT in patients with aggressive B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T cells. Clin Nucl Med. 2021;46(8):627\u201334. https:\/\/doi.org\/10.1097\/rlu.0000000000003756","journal-title":"Clin Nucl Med"},{"issue":"35","key":"6667_CR15","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/jco.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392. https:\/\/doi.org\/10.1200\/jco.21.01992","journal-title":"J Clin Oncol"},{"key":"6667_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355. https:\/\/doi.org\/10.1016\/j.blre.2018.11.002","journal-title":"Blood Rev"},{"issue":"21","key":"6667_CR17","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"issue":"6","key":"6667_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","volume":"41","author":"M Meignan","year":"2014","unstructured":"Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41(6):1113\u201322. https:\/\/doi.org\/10.1007\/s00259-014-2705-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6667_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques P, Ferrant E, Safar V, et al. Commercialanti-CD19 CART cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center. Am J Hematol. 2020;95(11):1324\u201333. https:\/\/doi.org\/10.1002\/ajh.25951","journal-title":"Am J Hematol"},{"issue":"9","key":"6667_CR20","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/bloodadvances.2021006715","volume":"6","author":"A Al Zaki","year":"2022","unstructured":"Al Zaki A, Feng L, Watson G, et al. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR\/SD after CAR T-cell therapy. Blood Adv. 2022;6(9):2867\u201371. https:\/\/doi.org\/10.1182\/bloodadvances.2021006715","journal-title":"Blood Adv"},{"issue":"3","key":"6667_CR21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00259-021-05551-5","volume":"49","author":"D Cohen","year":"2022","unstructured":"Cohen D, Luttwak E, Beyar-Katz O, et al. [18F] FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging. 2022;49(3):953\u201362. https:\/\/doi.org\/10.1007\/s00259-021-05551-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"6667_CR22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295\u2013312. https:\/\/doi.org\/10.1002\/ajh.26301","journal-title":"Am J Hematol"},{"key":"6667_CR23","doi-asserted-by":"publisher","unstructured":"Hong RM, Yin ETS, Wang LQ, et al. Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-cell therapy in non-hodgkin lymphoma. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.713577","DOI":"10.3389\/fonc.2021.713577"},{"issue":"3","key":"6667_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2967\/jnumed.119.238923","volume":"62","author":"SF Barrington","year":"2021","unstructured":"Barrington SF, Zwezerijnen BG, de Vet HC, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful? A study on behalf of the PETRA consortium. J Nucl Med. 2021;62(3):332\u20137. https:\/\/doi.org\/10.2967\/jnumed.119.238923","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06667-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06667-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06667-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T06:06:06Z","timestamp":1718345166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06667-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["6667"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06667-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"13 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. All included data were collected as part of a retrospective study protocol approved by the local institutional ethics committee, which waived written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}